Juglanin inhibits IL-1β-induced inflammation in human chondrocytes
Source abstract
Abstract
Osteoarthritis (OA) is one of the most characterized joint diseases associated with chondrocyte apoptosis. Juglanin has been reported to have anti-inflammation activity. This study aimed to evaluate the protective anti-inflammatory effects of juglanin in human OA chondrocytes. Human OA chondrocytes were pretreated with juglanin (10, 20 and 40 μM) for 2 h and subsequently stimulated with IL-1β for 24 h. Nitric oxide (NO) production was determined using the Griess method and prostaglandin E2 (PGE2), matrix metalloproteinase-3, -9 and -13 (MMP-3, MMP-9 and MMP-13), TNF-α, and IL-6 were assessed using ELISA. The expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), a disintegrin and metalloproteinase with thrombospondin motifs-4 and -5 (ADAMTS-4 and ADAMTS-5) were detected by qRT-PCR and western blot analysis. NF-κB signalling molecules were detected by western blot analysis. The results showed that juglanin dose-dependently suppressed PGE2, NO, MMP-1, MMP3, MMP13, TNF-α and IL-6 production induced by IL-1β. The expression of COX-2, iNOS, ADAMTS-4 and ADAMTS-5 induced by IL-1β were also suppressed by juglanin pretreatment. Western blot analysis showed that juglanin suppressed IL-1β-induced NF-κB activation. Taken together, we found that juglanin inhibits IL-1β-induced inflammation through the regulation of NF-κB signalling. Juglanin might be used as a therapeutic agent for treating OA.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Natural product bioactivities and synthesis · Nuts composition and effects · Osteoarthritis Treatment and Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopaedics, Huaihe Hospital of Henan University
Department of Orthopaedics, The Second People’s Hospital of Nanyang City
References (21)
Show source-provided references
1. 10.1038/boneres.2016.4410.1038/boneres.2016.44 ↗
2. 10.1016/j.joca.2015.01.00810.1016/j.joca.2015.01.008 ↗
3. 10.1016/j.biopha.2017.10.15210.1016/j.biopha.2017.10.152 ↗
4. 10.22203/eCM.v021a1610.22203/eCM.v021a16 ↗
5. 10.1155/2014/56145910.1155/2014/561459 ↗
6. 10.1016/j.abb.2019.05.02110.1016/j.abb.2019.05.021 ↗
7. 10.1097/01.blo.0000144854.66565.8f10.1097/01.blo.0000144854.66565.8f ↗
8. 10.1016/S0891-5849(02)01004-310.1016/S0891-5849(02)01004-3 ↗
9. 10.1002/bmc.129010.1002/bmc.1290 ↗
10. 10.1007/s11418-014-0817-010.1007/s11418-014-0817-0 ↗
11. 10.1016/j.biopha.2016.04.01310.1016/j.biopha.2016.04.013 ↗
12. 10.1055/s-0033-136027710.1055/s-0033-1360277 ↗
13. 10.1016/j.joca.2010.10.01910.1016/j.joca.2010.10.019 ↗
14. 10.1002/art.2072510.1002/art.20725 ↗
15. 10.3892/etm.2014.186210.3892/etm.2014.1862 ↗
16. 10.1038/nrrheum.2010.19610.1038/nrrheum.2010.196 ↗
17. 10.1016/j.ejphar.2009.09.01610.1016/j.ejphar.2009.09.016 ↗
18. 10.1016/j.intimp.2015.12.02410.1016/j.intimp.2015.12.024 ↗
19. 10.1002/1529-0131(200201)46:1<13::AID-ART497>3.0.CO;2-S10.1002/1529-0131(200201)46:1<13::AID-ART497>3.0.CO;2-S ↗
20. 10.1016/j.intimp.2018.09.04410.1016/j.intimp.2018.09.044 ↗
21. 10.1016/j.biopha.2018.02.13310.1016/j.biopha.2018.02.133 ↗